Barda selects edesa biotech's drug for u.s. funded platform trial in general ards

This phase 2 clinical study will evaluate paridiprubart (eb05) in hospitalized patients with acute respiratory distress syndrome (ards) due to a variety of causes. this barda-funded project is expected to complement edesa's ongoing drug development activities in covid-19 ards.
GM Ratings Summary
GM Quant Ranking